John Kuruvilla, Christopher Rushton, Diego Villa, Muhammad Aslam, Anca Prica, Nizar Abdel Samad, Stephane Doucet, Jill Dudebout, Isabelle Fleury, Graeme Fraser, Jean-Francois Larouche, Mona Shafey, Pamela Skrabek, Tanya Skamene, Ryan D. Morin, Miguel Alcaide, Susana Ben-Neriah, David Lee, Chad Winch, Lois E. Shepherd, David W. Scott, Michael Crump, Bingshu E. Chen, Annette E. Hay
{"title":"干细胞移植前伊布替尼和R-GDP治疗复发弥漫大B细胞淋巴瘤的随机试验","authors":"John Kuruvilla, Christopher Rushton, Diego Villa, Muhammad Aslam, Anca Prica, Nizar Abdel Samad, Stephane Doucet, Jill Dudebout, Isabelle Fleury, Graeme Fraser, Jean-Francois Larouche, Mona Shafey, Pamela Skrabek, Tanya Skamene, Ryan D. Morin, Miguel Alcaide, Susana Ben-Neriah, David Lee, Chad Winch, Lois E. Shepherd, David W. Scott, Michael Crump, Bingshu E. Chen, Annette E. Hay","doi":"10.1111/bjh.19764","DOIUrl":null,"url":null,"abstract":"<p>In the LY.17 randomized phase II clinical trial, adults with relapsed and refractory diffuse large B-cell lymphoma treated with ibrutinib-R-GDP (IR-GDP) for up to three cycles had more documented bacterial and fungal infections, without improvement in overall response, compared with R-GDP. CR, complete response; DLBCL, diffuse large B-cell lymphoma; PD, progressive disease; PR, partial response; R/R, relapsed/refractory; SD, stable disease.\n <figure>\n <div><picture>\n <source></source></picture><p></p>\n </div>\n </figure></p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"205 5","pages":"2067-2071"},"PeriodicalIF":3.8000,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A randomized trial of ibrutinib and R-GDP prior to stem cell transplant in relapsed diffuse large B-cell lymphoma\",\"authors\":\"John Kuruvilla, Christopher Rushton, Diego Villa, Muhammad Aslam, Anca Prica, Nizar Abdel Samad, Stephane Doucet, Jill Dudebout, Isabelle Fleury, Graeme Fraser, Jean-Francois Larouche, Mona Shafey, Pamela Skrabek, Tanya Skamene, Ryan D. Morin, Miguel Alcaide, Susana Ben-Neriah, David Lee, Chad Winch, Lois E. Shepherd, David W. Scott, Michael Crump, Bingshu E. Chen, Annette E. Hay\",\"doi\":\"10.1111/bjh.19764\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>In the LY.17 randomized phase II clinical trial, adults with relapsed and refractory diffuse large B-cell lymphoma treated with ibrutinib-R-GDP (IR-GDP) for up to three cycles had more documented bacterial and fungal infections, without improvement in overall response, compared with R-GDP. CR, complete response; DLBCL, diffuse large B-cell lymphoma; PD, progressive disease; PR, partial response; R/R, relapsed/refractory; SD, stable disease.\\n <figure>\\n <div><picture>\\n <source></source></picture><p></p>\\n </div>\\n </figure></p>\",\"PeriodicalId\":135,\"journal\":{\"name\":\"British Journal of Haematology\",\"volume\":\"205 5\",\"pages\":\"2067-2071\"},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2024-09-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"British Journal of Haematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/bjh.19764\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Haematology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/bjh.19764","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
A randomized trial of ibrutinib and R-GDP prior to stem cell transplant in relapsed diffuse large B-cell lymphoma
In the LY.17 randomized phase II clinical trial, adults with relapsed and refractory diffuse large B-cell lymphoma treated with ibrutinib-R-GDP (IR-GDP) for up to three cycles had more documented bacterial and fungal infections, without improvement in overall response, compared with R-GDP. CR, complete response; DLBCL, diffuse large B-cell lymphoma; PD, progressive disease; PR, partial response; R/R, relapsed/refractory; SD, stable disease.
期刊介绍：
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
